Link Cell Therapies key facts
as of Oct 2026- Developer of cell therapies designed to help doctors detect solid cancer tumors.
- Link Cell Therapies is valued at approximately $110.5M as of Oct 2026 (last reported valuation).
- It has raised $72.0M; the latest was Early Stage VC ($60.0M) in Dec 2025.
- Notable investors include Wing Venture Capital, Johnson & Johnson JJDC, Samsara BioCapital, Bristol-Myers Squibb, Kyowa Kirin — 7 tracked in total.
- Status: Privately Held (backing).
Link Cell Therapies's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·Watch Link Cell Therapies: the Monday email on marks, rounds and moves
Link Cell Therapies funding rounds
No funding rounds for Link Cell Therapies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Link Cell Therapies valuation
Link Cell Therapies's last reported valuation was $111 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Link Cell Therapies investors
7 investors are on record for Link Cell Therapies, including Wing Venture Capital, Johnson & Johnson JJDC, Samsara BioCapital and Bristol-Myers Squibb.
About Link Cell Therapies
Developer of cell therapies designed to help doctors detect solid cancer tumors. The company offers cancer cell therapy and the development of safe and effective CAR T agents, and an advanced suite of exciting therapeutic programs, enabling cancer patients with cancer indications, including solid tumors and certain haematologic cancers and helping to kill tumor cells while sparing healthy tissue.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2022
- Employees
- 23
- Website
- linkcelltx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.